These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6779315)

  • 61. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice.
    Iwata S; Izumi K; Nomoto M
    Pharmacol Biochem Behav; 1992 Aug; 42(4):803-8. PubMed ID: 1513862
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment.
    Agnati LF; Fuxe K; Benfenati F; Battistini N; Zini I; Toffano G
    Neurosci Lett; 1983 Oct; 40(3):293-7. PubMed ID: 6646502
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A comparative study of [3H]haloperidol and [3H]spiroperidol binding to receptors on rat cerebral membranes.
    Howlett DR; Nahorski SR
    FEBS Lett; 1978 Mar; 87(1):152-6. PubMed ID: 631328
    [No Abstract]   [Full Text] [Related]  

  • 65. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
    Friedhoff AJ; Bonnet K; Tosengarten H
    Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
    Fayle P; Jackson DM; Jenkins OF; Lafferty PA
    Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dopamine D2 receptors in the striatum and frontal cortex following chronic administration of haloperidol.
    Liskowsky DR; Potter LT
    Neuropharmacology; 1987 May; 26(5):481-3. PubMed ID: 2955242
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chronic rubidium does not prevent dopamine receptor supersensitivity.
    Bannet J; Ebstein RP; Hershkowitz M; Belmaker RH
    Neuropsychobiology; 1982; 8(6):281-3. PubMed ID: 6298653
    [No Abstract]   [Full Text] [Related]  

  • 69. Effect of duration of haloperidol treatment on DA receptor supersensitization in aging C57BL/6J mice.
    Randall PK; Severson JA; Hurd SM; McClure WO
    Brain Res; 1985 Apr; 333(1):85-95. PubMed ID: 4039618
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors.
    Prosser ES; Csernansky JG; Hollister LE
    Life Sci; 1988; 43(8):715-20. PubMed ID: 2901023
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [3H]Haloperidol and [3H]spiroperidol binding in rat striatum during ageing.
    Govoni S; Spano PF; Trabucchi M
    J Pharm Pharmacol; 1978 Jul; 30(7):448-9. PubMed ID: 27613
    [No Abstract]   [Full Text] [Related]  

  • 72. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics.
    Fields JZ; Gordon JH
    Life Sci; 1982 Jan; 30(3):229-34. PubMed ID: 7200183
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Motor effects of calcitonin administered intracerebroventricularly in the rat.
    Twery MJ; Kirkpatrick B; Critcher EC; Lewis MH; Mailman RB; Cooper CW
    Eur J Pharmacol; 1986 Feb; 121(2):189-98. PubMed ID: 3699092
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
    See RE; Aravagiri M; Ellison GD
    Life Sci; 1989; 44(3):229-36. PubMed ID: 2536879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain.
    Reches A; Wagner HR; Jiang D; Jackson V; Fahn S
    Life Sci; 1982 Jul; 31(1):37-44. PubMed ID: 7109853
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia.
    Delfs JM; Ellison GD; Mercugliano M; Chesselet MF
    Exp Neurol; 1995 Jun; 133(2):175-88. PubMed ID: 7544289
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Study on some compensatory responses of dopaminergic system in aging rats.
    Algeri S; Achilli G; Cimino M; Perego C; Ponzio F; Vantini G
    Exp Brain Res; 1982; Suppl 5():146-52. PubMed ID: 7151906
    [No Abstract]   [Full Text] [Related]  

  • 79. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
    Severson JA; Robinson HE; Simpson GM
    Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clozapine in tardive dyskinesia: observations from human and animal model studies.
    Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.